View More Recent Stories

Jun 21, 2022 08:17AM Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
Jun 7, 2022 07:05AM Kiromic BioPharma (KRBP) Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
Jun 7, 2022 07:05AM Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
May 13, 2022 08:08AM Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 11, 2022 06:58AM Kiromic BioPharma (KRBP) to Directly Submit Amended IND for Procel to FDA in H2'22
May 11, 2022 06:58AM Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022
Apr 11, 2022 04:03PM Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation
Apr 8, 2022 04:09PM Kiromic BioPharma (KRBP) Reports FY 2021 Net Loss of $25.59M, Cash Position of $25.35M, Provides Recent Corporate Highlights
Apr 8, 2022 04:07PM Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights
Apr 1, 2022 07:07AM Kiromic Biopharma Announces Filing of Form 12b-25
Mar 11, 2022 04:03PM Kiromic BioPharma (KRBP) Issues Business Update; Reports Q3 Results
Mar 11, 2022 04:02PM Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results
Feb 3, 2022 08:59AM Kiromic BioPharma (KRBP) Announces Management and Board Changes
Feb 3, 2022 08:58AM Kiromic BioPharma Announces Changes in Management, Board of Directors
Feb 3, 2022 08:02AM Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company’s Board of Directors
Nov 24, 2021 04:12PM Kiromic BioPharma (KRBP) Receives Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Nov 24, 2021 04:12PM Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Oct 25, 2021 07:04AM Kiromic BioPharma (KRBP) Reports New Data Showing Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01
Oct 25, 2021 07:03AM Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer
View More Recent Stories